CERO THERAPEUTICS HOLDINGS, INC. 8-K

What Happened
On January 7, 2026, CERo Therapeutics Holdings, Inc. (CERO) filed a Form 8-K to disclose a clinical update for its CER-1236 Phase 1 trial in acute myeloid leukemia (CertainT-1). The company published an investor presentation (Exhibit 99.1) and issued a press release (Exhibit 99.2) titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.”

Key Details

• Filing date: January 7, 2026 (Form 8-K Items 7.01 and 8.01).
• Trial/drug: CER-1236, Phase 1 trial called CertainT-1 targeting AML.
• Update highlights: company emphasizes key safety data and reports a platelet transfusion‑free interval observed in a patient with myelodysplastic syndrome/AML.
• Materials furnished: investor presentation (Exhibit 99.1) and press release (Exhibit 99.2) were provided with the filing.

Why It Matters
Clinical updates in early-stage trials provide investors with information on safety signals and early clinical observations that can affect perceptions of a drug candidate’s development progress and potential value. This 8-K does not report regulatory decisions or trial results beyond the safety and transfusion-free observation noted; investors should review the attached presentation and press release for full details and await further data or company guidance for implications on timelines or milestones.